

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND
DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED 30
SEPTEMBER 2024
TOGETHER WITH REVIEW REPORT**

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

Interim condensed consolidated financial statements

For the three-month and nine-month periods ended 30 September 2024

Table of Contents	Page
Review Report	3
Interim Condensed Consolidated Statement of Financial Position	4
Interim Condensed Consolidated Statement of Profit or Loss	5
Interim Condensed Consolidated Statement of Comprehensive Income	6
Interim Condensed Consolidated Statement of Changes in Equity	7
Interim Condensed Consolidated Statement of Cash Flows	8
Notes to the Interim Condensed Consolidated Financial Statements	9-26

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF THE BOARD OF DIRECTORS OF TENTH OF RAMADAN FOR
PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)
ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

Introduction


We have reviewed the accompanying interim condensed consolidated financial position of **TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)** as of 30 September 2024 and the related interim condensed consolidated statements of profit or loss, comprehensive income for the three-month and nine-month periods, and changes in equity and cash flows for the nine-month periods then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and fair presentation of these condensed interim consolidated financial statements in accordance with Egyptian Accounting Standard No. (30) "Interim Financial Statements", Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with Egyptian Standard on Review Engagements No. 2410, "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity." A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim condensed consolidated financial statements.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements does not give a true and fair view, in all material respects, of the financial position of the entity as at 30 September 2024, and of its financial performance and its cash flows for the nine month period ended 30 September 2024 in accordance with Egyptian Accounting Standard No. (30) "Interim Financial Statements".



Cairo: 14 November 2024

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As At 30 September 2024

	Notes	30 September 2024	31 December 2023
		EGP	EGP
ASSETS			
Non-current assets			
Fixed assets and projects under construction	(5)	585,027,306	593,657,768
Right of use assets	(6-A)	9,365,910	12,391,296
Intangible assets	(7)	565,445,090	589,271,529
Total non-current assets		1,159,838,306	1,195,320,593
Current assets			
Inventories	(8)	493,092,159	303,260,502
Trade and notes receivable	(9)	1,148,008,285	1,271,742,277
Treasury bills	(10)	227,280,742	260,895,424
Due from related parties		25,500	25,500
Prepayments and other receivables		386,563,652	134,669,448
Cash on hand and at banks	(11)	83,323,821	52,358,275
Other Assets	(12)	93,839,078	-
Total current assets		2,432,133,237	2,022,951,426
TOTAL ASSETS		3,591,971,543	3,218,272,019
EQUITY AND LIABILITIES			
Equity			
Paid up Capital	(15)	378,233,733	375,000,000
Legal reserve		136,722,790	125,000,000
General reserve	(16)	379,904,021	377,699,726
Treasury Shares	(17)	(26,231,267)	(26,231,267)
Share based payments reserve	(18)	8,374,699	13,927,085
Other reserves		278,952	278,952
Profits for the period / year and retained earnings		1,009,486,408	896,888,242
Total equity of Parent Company		1,886,769,336	1,762,562,738
Non-controlling interest		22,448,978	12,936,522
Total equity		1,909,218,314	1,775,499,260
LIABILITIES			
Non-current liabilities			
Lease liabilities – Noncurrent portion	(6-B)	7,305,168	11,699,588
Deferred tax liabilities	(26)	80,030,342	58,234,398
Total non-current liabilities		87,335,510	69,933,986
Current liabilities			
Provisions	(13)	17,220,844	15,034,468
Credit facilities	(19)	1,116,029,126	1,060,221,318
Lease liabilities – Current portion	(6-B)	4,357,156	4,807,464
Trade, notes payables and other payables	(14)	409,703,603	232,184,692
Income taxes payable		48,106,990	60,590,831
Total current liabilities		1,595,417,719	1,372,838,773
TOTAL LIABILITIES		1,682,753,229	1,442,772,759
TOTAL LIABILITIES AND EQUITY		3,591,971,543	3,218,272,019

Finance Director

Mohamed Abo Amra



Board Member

Amr Abdallah Morsy



The accompanying notes from (1) to (30) are an integral part of these interim condensed consolidated financial statements.
Review Report Attached

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
For the three-month and nine-month periods ended 30 September 2024

	Notes	Nine Months Ended		Three Months Ended	
		30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Revenues	(20)	1,784,368,572	1,388,158,543	763,229,072	545,724,720
Cost of revenues	(21)	(968,851,972)	(736,342,512)	(416,140,917)	(280,633,540)
GROSS PROFIT		815,516,600	651,816,031	347,088,155	265,091,180
Selling and marketing expenses	(22)	(300,159,063)	(248,413,614)	(97,467,310)	(93,611,476)
General and administrative expenses	(23)	(78,949,341)	(64,138,476)	(25,569,918)	(22,351,475)
Other income		4,150,355	1,861,653	1,467,306	633,689
OPERATING PROFIT		440,558,551	341,125,594	225,518,233	149,761,918
Finance income	(24)	51,141,160	47,609,639	16,548,908	16,838,457
Finance expenses	(25)	(205,343,831)	(134,684,421)	(66,846,865)	(58,550,318)
Net foreign exchange gain (loss)		52,387,192	19,657,527	(322,237)	484,987
NET FINANCE COST		(101,815,479)	(67,417,255)	(50,620,194)	(41,226,874)
Impairment of trade and notes receivable	(9)	(5,687,434)	(2,621,810)	(5,372,089)	(872,340)
Provisions	(13)	(500,000)	(415,186)	-	-
Share Based payment expenses		(10,468,374)	(12,672,380)	(10,468,374)	(6,136,100)
Contribution for health insurance		(4,814,824)	(3,682,665)	(2,001,318)	(1,427,068)
PROFITS FOR THE PERIOD BEFORE INCOME TAXES		317,272,440	254,316,298	157,056,258	100,099,536
Income taxes	(26)	(73,236,810)	(57,337,323)	(36,630,568)	(22,133,279)
PROFITS FOR THE PERIOD		244,035,630	196,978,975	120,425,690	77,966,257
Attributable to:					
Equity holders of the Parent Company		234,523,174	191,963,850	115,678,403	76,288,972
Non-controlling interests		9,512,456	5,015,125	4,747,287	1,677,285
		244,035,630	196,978,975	120,425,690	77,966,257
Basic Earnings Per Share	(27)	0.1570	0.1288	0.0774	0.0512
Diluted Earnings Per Share	(27)	0.1564	0.1282	0.0772	0.0510

Finance Director

Mohamed Abo Amira



Board Member

Amr Abdallah Morsy



The accompanying notes from (1) to (30) are an integral part of these interim condensed consolidated financial statements.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three-month and nine-month periods ended 30 September 2024

	<i>30 September 2024 EGP</i>	<i>30 September 2023 EGP</i>	<i>30 September 2024 EGP</i>	<i>30 September 2023 EGP</i>
PROFITS FOR THE PERIOD	244,035,630	196,978,975	120,425,690	77,966,257
OTHER COMPREHENSIVE INCOME	-	-	-	-
TOTAL COMPREHENSIVE INCOME	244,035,630	196,978,975	120,425,690	77,966,257
Attributable to				
Equity holders of the Parent Company	234,523,174	191,963,850	115,678,403	76,288,972
Non-controlling interest	9,512,456	5,015,125	4,747,287	1,677,285
	244,035,630	196,978,975	120,425,690	77,966,257

The accompanying notes from (1) to (30) are an integral part of these interim condensed consolidated financial statements.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

For the three-month and nine-month periods ended 30 September 2024

	<i>Paid up capital</i>	<i>Paid under capital increase</i>	<i>Legal reserve</i>	<i>General reserve</i>	<i>Treasury Shares</i>	<i>Share based payment reserve</i>	<i>Other reserves</i>	<i>Profits for the period / and retained earnings</i>	<i>Total equity of parent company</i>	<i>Non-controlling interest</i>	<i>Total</i>
	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>
Balance as at 1 January 2023	250,000,000	160,606	125,000,000	397,521,390	(65,926,198)	14,873,268	278,952	796,678,613	1,518,586,631	4,590,062	1,523,176,693
Paid under capital increase (Note 15)	-	1,952,074	-	-	-	-	-	-	1,952,074	-	1,952,074
Transferred from paid under increase to capital increase (Note 15)	2,112,680	(2,112,680)	-	-	-	-	-	-	-	-	-
Transferred from retained earnings to capital increase (Note 15)	127,887,320	-	-	-	-	-	-	(127,887,320)	-	-	-
Retire treasury shares (Note 17)	(5,000,000)	-	-	(34,694,932)	39,694,932	-	-	-	-	-	-
Share based payment reserve	-	-	-	-	-	10,105,363	-	-	10,105,363	-	10,105,363
Transferred from shared based payment reserve to general reserve	-	-	-	14,873,268	-	(14,873,268)	-	-	-	-	-
Dividend distributions	-	-	-	-	-	-	-	(16,762,500)	(16,762,500)	-	(16,762,500)
Total comprehensive income for the period	-	-	-	-	-	-	-	191,963,850	191,963,850	5,015,125	196,978,975
Balance as at 30 September 2023	<u>375,000,000</u>	<u>-</u>	<u>125,000,000</u>	<u>377,699,726</u>	<u>(26,231,266)</u>	<u>10,105,363</u>	<u>278,952</u>	<u>843,992,643</u>	<u>1,705,845,418</u>	<u>9,605,187</u>	<u>1,715,450,605</u>
Balance as at 1 January 2024	375,000,000	-	125,000,000	377,699,726	(26,231,267)	13,927,085	278,952	896,888,242	1,762,562,738	12,936,522	1,775,499,260
Payments to capital increase (Note 15)	3,233,733	-	-	-	-	-	-	-	3,233,733	-	3,233,733
Transferred to legal	-	-	11,722,790	(11,722,790)	-	-	-	-	-	-	-
Transferred form shared based payments reserve to general reserve	-	-	-	13,927,085	-	(13,927,085)	-	-	-	-	-
Share based payment reserve (Note 18)	-	-	-	-	-	8,374,699	-	-	8,374,699	-	8,374,699
Dividend distributions	-	-	-	-	-	-	-	(121,925,008)	(121,925,008)	-	(121,925,008)
Total comprehensive income for the period	-	-	-	-	-	-	-	234,523,174	234,523,174	9,512,456	244,035,630
Balance as at 30 September 2024	<u>378,233,733</u>	<u>-</u>	<u>136,722,790</u>	<u>379,904,021</u>	<u>(26,231,267)</u>	<u>8,374,699</u>	<u>278,952</u>	<u>1,009,486,408</u>	<u>1,886,769,336</u>	<u>22,448,978</u>	<u>1,909,218,314</u>

The accompanying notes from (1) to (30) are an integral part of these interim condensed consolidated financial statements.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the three-month and nine-month periods ended 30 September 2024

	Notes	30 September 2024 EGP	30 September 2023 EGP
OPERATING ACTIVITIES			
Profits for the period before income taxes		317,272,440	254,316,298
Adjustments to reconcile profit before tax to net cash flow:			
Net foreign exchange differences		(64,386,891)	(2,536,937)
Depreciation and amortization	(5,6,7)	60,491,120	52,928,910
Share based payment expense		10,468,374	12,672,380
Provision charged	(13)	2,186,376	415,186
Impairment of trade and notes receivable	(9)	5,687,434	2,621,811
Write down of inventory	(8)	11,919,274	25,953,769
Finance income		(50,439,243)	(46,940,704)
Finance expenses	(25)	204,164,012	133,121,682
Unwinding interests of lease liabilities	(25)	1,179,819	1,562,739
(Gain) from sale of fixed assets	(5)	(6,858)	(103,718)
		<u>498,535,857</u>	<u>434,011,416</u>
Change in inventories		(183,147,446)	(34,132,988)
Used of inventory provision		(18,603,484)	(11,378,443)
Change in trade and notes receivable		118,046,558	(350,267,168)
Change in prepayments and other receivables		(235,202,084)	(29,598,980)
Change in trade, notes payables and other payable		98,434,517	78,041,638
Cash flows provided from operating activities		<u>278,063,918</u>	<u>86,675,475</u>
Debit interests paid		(197,823,303)	(122,281,084)
Provisions used		-	(263,186)
Income taxes paid		(63,924,708)	(57,954,978)
NET CASH FLOWS PROVIDED FROM (USED IN) OPERATING ACTIVITIES		<u>16,315,907</u>	<u>(93,823,773)</u>
INVESTING ACTIVITIES			
Payments to acquire fixed assets	(5)	(17,820,546)	(13,876,272)
Payments to acquire assets under construction	(5)	(5,838,384)	(44,256,105)
Payments for other Assets	(12)	(93,839,078)	-
Payments to acquire intangible assets	(7)	(1,395,000)	(151,070,433)
Payment to acquire treasury bills		(552,722,588)	(468,797,943)
Matured treasury bills collection		435,100,000	509,700,000
Sale of Treasury bills		184,984,394	99,106,671
Proceeds from sale of fixed assets	(5)	51,955	121,066
Investment in term deposits	(11)	(9,644)	3,726,872
NET CASH FLOWS (USED IN) INVESTING ACTIVITIES		<u>(51,488,891)</u>	<u>(65,346,144)</u>
FINANCING ACTIVITIES			
Payments to capital increase	(15)	3,233,733	2,112,680
Credit facilities used	(19)	1,488,256,248	1,088,382,440
Payment of credit facilities	(19)	(1,432,448,439)	(871,874,246)
Dividends paid		(51,275,000)	(16,762,500)
Lease payments paid during the period		(6,024,547)	(4,663,465)
NET CASH FLOWS PROVIDED FROM FINANCING ACTIVITIES		<u>1,741,995</u>	<u>197,194,909</u>
Net change in cash and cash equivalent during the period		<u>(33,430,989)</u>	<u>38,024,992</u>
Net foreign exchange difference		64,386,891	2,536,937
Cash and cash equivalent - beginning of the period		51,953,135	19,579,917
CASH AND CASH EQUIVALENT - END OF THE PERIOD	(11)	<u>82,909,037</u>	<u>60,141,846</u>

The accompanying notes from (1) to (30) are an integral part of these interim condensed consolidated financial statements.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

1- BACKGROUND

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (the “Company” or the “Parent Company”) was established under the provisions of Law No. 43 of 1974.

The Company was registered in the commercial registry under No.84008 on 15 January 1986.

The listing of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) on the Egyptian stock exchange was approved in 26 November 2019 according to resolution of listing committee of Egyptian stock exchange.

The registered office is located at plot No. 5 Second Industrial Zone, 6th of October City – Giza– Egypt. The consolidated financial statements include the separate financial statements of the Parent Company and its subsidiaries (collectively referred to as the “Group”).

The Group is principally engaged in:

- Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use.
- Manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals.
- Importing pharmaceutical reagents and raw materials necessary for serving the Company’s purposes without trading.
- Producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others.
- Producing food supplements for human use for others and by others.

Below is a brief background about the subsidiaries:

Rameda for Pharmaceuticals Trading Company

A subsidiary with 99.97% shareholding. Its principal activity is importing and exporting pharmaceutical reagents, producing, marketing, selling and storing of pharmaceutical reagents and producing pharmaceutical reagents for human and veterinary and diagnostic use for others

Ramecare Company

A subsidiary with 49% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

It was considered a subsidiary since the Parent Company is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over it.

Ramepharma Company

A subsidiary with 49% legal ownership. Its principal activity is producing, marketing, selling and storing of pharmaceutical reagents, producing pharmaceutical reagents for human and veterinary and diagnostic use for others.

It was considered a subsidiary since the Parent Company is exposed, or has rights, to variable returns from its involvement with the subsidiary and has the ability to affect those returns through its power over it.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

2- SIGNIFICANT ACCOUNTING POLICIES

2-1 BASIS OF PREPARATION CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements of the Group have been prepared in accordance with the Egyptian accounting standards Num (30) and the applicable laws and regulations, The condensed financial statements do not include all the financial statements and disclosures required in the annual financial statements, and should be read in conjunction with the financial statements for the year ending December 31, 2023. In addition, the results of the interim period ending September 30, 2024 may not be considered an accurate indication of the expected results for the financial year. On December 31, 2024.

The consolidated financial statements are prepared under the going concern assumption on a historical cost basis, and The Company is not subject to any significant seasonal or cyclical effects.

The consolidated financial statements are prepared and presented in Egyptian pounds, which is the Group's functional currency.

2-2 SIGNIFICANT ACCOUNTING POLICIES

The accounting policies used in the preparation of the condensed consolidated interim financial statements are consistent with those used in the preparation of the consolidated financial statements for the year ending on December 31, 2023.

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of these interim condensed consolidated financial statements requires management to make judgments and estimates that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities at the reporting date. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the assets or liabilities affected in future periods.

3-1 Judgments

Revenue Recognition for sale of goods

In making their judgment, the management considered the detailed criteria for the recognition of revenue from the sale of goods as set out in EAS (48) "Revenue from contracts with customers" including the judgement about whether significant risks and rewards have been transferred.

3-2 Estimates

Impairment of trade and other receivables

An estimate of the collectible amount of trade and other receivables is made when collection of the full amount is no longer probable. For individually significant amounts, this estimate is performed on an individual basis. Amounts which are not individually significant, but are past due, are assessed collectively and a provision is applied according to the length of time past due, based on historical recovery rates.

Provision for sales returns

The Group's management determines the estimates provision for the expected sales returns. This estimate is determined after considering the past experience of sales returns and sales volume and expiry dates of the products sold. The management periodically reviews the estimated provision amount to ensure that provision is adequate to cover the sales return.

Useful lives of fixed assets

The Group's management determines the estimated useful lives of its fixed assets for calculating depreciation. This estimate is determined after considering the expected usage of the asset or physical wear and tear. The management periodically reviews the estimated useful lives and the depreciation method to ensure that the method and the period of depreciation are consistent with the expected pattern of economic benefits from these assets.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES - CONTINUED

3-2 Estimates - Continued

Useful lives of intangible assets

The useful lives of intangible assets are assessed as finite. The management periodically reviews the estimated useful lives and the amortization method to ensure that the method and the period of amortization are consistent with the expected pattern of economic benefits from these assets.

Taxes

The Group is subject to income taxes in Egypt. Significant judgment is required to determine the total provision for current and deferred taxes. The Group establishes provision, based on reasonable estimates, for possible consequences of audits by the tax authorities in Egypt. The amount of such provision is based on various factors, such as experience of previous tax audits and different interpretations of tax regulations by the Group and the responsible tax authority. Such differences of interpretations may be on a wide variety of issues depending on the conditions prevailing in Egypt.

Deferred tax assets are recognized for unused accumulated tax losses to the extent that it is probable that taxable profits will be available against which the losses can be utilized. Significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Impairment of non-financial assets

The Group assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. The non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. When value in use calculations are undertaken, management estimates the expected future cash flows from the asset or cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows.

4- SEGMENT INFORMATION

Currently the Group's primary business segment is the production and selling of pharmaceutical products which contributes to 93% of total revenue and balance 7% is contributed by toll manufacturing services (30 September 2023: 92% and 8% receptively). The Group's management monitors the business under two segments, "production and selling of pharmaceutical products" and "manufacturing for others" (Toll manufacturing) for the purpose of making business decisions.

Segment performance is evaluated based on revenue and measured consistently with revenue in the interim condensed consolidated financial statements.

Accordingly, the Group's revenues during the period ended 30 September 2024 and 30 September 2023 were reported under two segments in the interim condensed consolidated financial statements.

The Group produces and sells several pharmaceutical products and renders services as follows:

Period	<i>Services</i>	<i>Sales of pharmaceutical products</i>			<i>Total</i> <i>EGP</i>
	<i>Toll</i> <i>Manufacturing</i> <i>"Domestic"</i> <i>EGP</i>	<i>Export</i> <i>EGP</i>	<i>Domestic</i>		
			<i>Private sales</i>	<i>Tenders</i>	
			<i>EGP</i>	<i>EGP</i>	
30 September 2024	117,189,845	139,123,377	1,411,877,985	116,177,365	1,784,368,572
30 September 2023	105,305,365	140,342,219	997,047,510	145,463,449	1,388,158,543

Revenue from the top five customers presented 77% of total pharmaceutical products revenues (30 September 2023: 82%).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

For the three-month and nine-month periods ended 30 September 2024

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
As of 1 January 2024	18,637,425	288,432,792	482,794,175	16,060,164	35,186,599	11,571,461	39,423,718	38,090,575	930,196,909
Additions	-	3,759,811	5,411,727	2,166,740	268,527	1,102,950	5,110,791	5,838,384	23,658,930
Transferred from assets under construction	-	2,575,827	28,565,362	-	-	-	-	(31,141,189)	-
Disposals	-	-	-	-	-	(53,736)	(68,929)	-	(122,665)
As of 30 September 2024	18,637,425	294,768,430	516,771,264	18,226,904	35,455,126	12,620,675	44,465,580	12,787,770	953,733,174
Accumulated depreciation									
As of 1 January 2024	-	(84,033,388)	(198,803,696)	(12,303,486)	14,143,898	(3,642,757)	(23,611,916)	-	(336,539,141)
Depreciation for the period	-	(7,149,904)	(18,158,350)	(728,842)	(2,460,061)	(807,334)	(2,939,804)	-	(32,244,295)
Disposals	-	-	-	-	-	28,647	48,921	-	77,568
As of 30 September 2024	-	(91,183,292)	(216,962,046)	(13,032,328)	16,603,959)	(4,421,444)	(26,502,799)	-	(368,705,868)
Net book value as of 30 September 2024	18,637,425	203,585,138	299,809,218	5,194,576	18,851,167	8,199,231	17,962,781	12,787,770	585,027,306

- The cost of fixed assets as of 30 September 2024 includes EGP 113,303,440 which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 30 September 2024 includes impairment by EGP 686,437 EGP 686,437 as at 31 December 2023).
- Depreciation for the period was allocated to the statement of profit or loss as follows:

	<i>30 September 2024</i> <i>EGP</i>	<i>30 September 2024</i> <i>EGP</i>
Cost of revenue	29,706,692	
Selling and marketing expenses	958,478	
General and administrative expenses	1,579,125	
	32,244,295	
		122,665
Cost of disposed assets		(77,568)
Accumulated depreciation of disposed assets		45,097
Net book value of disposed assets		51,955
Proceeds from sale of fixed assets		6,858
Gains from sale of fixed assets		6,858

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

For the three-month and nine-month periods ended 30 September 2024

5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION - CONTINUED

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
As of 1 January 2023	18,637,425	279,172,534	444,859,590	16,305,904	31,982,677	7,345,392	33,111,400	12,858,215	844,273,137
Additions	-	4,799,190	5,093,589	-	3,203,922	4,226,069	5,345,713	68,376,758	91,045,241
Transferred from assets under construction	-	4,461,068	37,268,407	-	-	-	1,414,923	(43,144,398)	-
Disposals	-	-	(4,427,411)	(245,740)	-	-	(448,318)	-	(5,121,469)
As of 31 December 2023	18,637,425	288,432,792	482,794,175	16,060,164	35,186,599	11,571,461	39,423,718	38,090,575	930,196,909
Accumulated depreciation									
As of 1 January 2023	-	(74,889,887)	(182,460,484)	(11,707,422)	(11,027,525)	(2,818,251)	(20,604,244)	-	(303,507,813)
Depreciation for the year	-	(9,143,501)	(20,755,328)	(841,804)	(3,116,373)	(824,506)	(3,429,323)	-	(38,110,835)
Disposals	-	-	4,412,116	245,740	-	-	421,651	-	5,079,507
As of 31 December 2023	-	(84,033,388)	(198,803,696)	(12,303,486)	(14,143,898)	(3,642,757)	(23,611,916)	-	(336,539,141)
Net book value as of 31 December 2023	18,637,425	204,399,404	283,990,479	3,756,678	21,042,701	7,928,704	15,811,802	38,090,575	593,657,768

- The cost of fixed assets as of 31 December 2023 includes EGP 110,490,122 which represents fully depreciated assets that are still in use.

- The cost of asset under construction includes impairment by EGP 686,437.

- Depreciation for the year was allocated to the statement of profit or loss as follows:

	31 December 2023 EGP
Cost of revenue	35,018,353
Selling and marketing expenses	1,089,220
General and administrative expenses	2,003,262
	<u>38,110,835</u>

Gain from sale of fixed assets was calculated as follows:

	31 December 2023 EGP
Cost of disposed assets	5,121,469
Accumulated depreciation of disposed assets	(5,079,507)
Net book value of disposed assets	41,962
Proceeds from sale of fixed assets	182,572
Gain from sale of fixed assets	<u>140,610</u>

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

6- LEASES

Right of use assets are scientific rental offices, operating leases, and warehouses

A) Right of use assets

	<i>30 September 2024</i>	<i>31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>
Cost at beginning of period / year	28,026,090	27,817,376
Additions	-	208,714
Total cost at end of period / year	28,026,090	28,026,090
Accumulated amortization at beginning of period / year	(15,634,794)	(11,601,816)
Amortization for the period / year	(3,025,386)	(4,032,978)
Accumulated amortization at end of period / year	(18,660,180)	(15,634,794)
Net book value at end of period / year	9,365,910	12,391,296

B) Lease liability

	<i>30 September 2024</i>	<i>31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>
Cost at beginning of period / year	16,507,052	20,007,158
Additions	-	208,714
Unwinding interests of lease liabilities during the period / year	1,179,819	2,035,503
Lease payments paid during the period	(6,024,547)	(5,744,323)
As at end of period / year	11,662,324	16,507,052
Deduct: Current portion	4,357,156	4,807,464
Non-current portion	7,305,168	11,699,588

7- INTANGIBLE ASSETS

	Registration Rights	
	<i>30 September 2024</i>	<i>31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>
Cost at beginning of period / year	680,492,842	518,048,757
Additions	1,395,000	162,444,085
Total cost at end of period / year	681,887,842	680,492,842
Accumulated amortization at beginning of period / year	(91,221,313)	(60,481,138)
Amortization for the period / year	(25,221,439)	(30,740,175)
Accumulated amortization at end of period / year	(116,442,752)	(91,221,313)
Net book value at end of period / year	565,445,090	589,271,529

- The balance of the intangible assets represents the cost of acquiring the registration rights of certain pharmaceutical products and is amortized using the straight-line method over their useful life (20 periods).
- Management estimate the expected future benefit of the registration rights to be utilize over 20 periods and assessed for impaired whenever there is an indication that the economic benefit of the product is impaired.
- Intangible asset balance includes registration right assets under approval amounted to EGP 13,968,020 (31 December 2023: EGP 13,439,970).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

8- INVENTORIES

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Raw materials	230,741,275	111,944,615
Packing and packaging materials	81,794,241	73,593,369
Spare parts	32,505,024	19,850,409
Finished goods	51,340,429	89,060,232
Work in progress	33,829,125	24,630,447
Goods in transit	33,696,058	7,329,099
Inventory with others	47,337,454	1,687,988
	<u>511,243,606</u>	<u>328,096,159</u>
Write down in inventories	(18,151,447)	(24,835,657)
	<u><u>493,092,159</u></u>	<u><u>303,260,502</u></u>

The movement in the write down in value of inventories is as follows:

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Beginning balance period / year	(24,835,657)	(10,656,360)
Charged during the period / year *	(11,919,274)	(34,022,291)
Used of inventory provision	18,603,484	19,842,994
Ending balance period / year	<u>(18,151,447)</u>	<u>(24,835,657)</u>

*The write down in value of inventories during the period / year was included in the cost of sales.

9- TRADE AND NOTES RECEIVABLES

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Trade receivable	579,579,932	331,578,953
Trade receivable – toll manufacturing	34,644,152	36,863,339
Notes receivable	554,178,522	918,006,872
	<u>1,168,402,606</u>	<u>1,286,449,164</u>
Impairment in value of trade and notes receivables	(20,394,321)	(14,706,887)
	<u><u>1,148,008,285</u></u>	<u><u>1,271,742,277</u></u>

Notes receivable amounting to 242 M EGP are mortgage as a guarantee for the credit facilities (note 19).

The movement of the impairment in value of trade receivable is as follows:

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Balance at beginning of period / year	(14,706,887)	(10,898,308)
Charged during the period / year	(5,727,608)	(3,808,579)
No longer required	40,174	-
Balance at end of period / year	<u>(20,394,321)</u>	<u>(14,706,887)</u>

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

10- TREASURY BILLS

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Treasury bills	282,875,000	283,900,000
Unearned interest	(55,594,258)	(23,004,576)
Balance at end of period / year	<u>227,280,742</u>	<u>260,895,424</u>

11- CASH ON HAND AND AT BANKS

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
a) Egyptian Pounds		
Cash on hand	1,051	32,433
Current accounts	68,354,789	25,777,065
Checks under collection	3,962,686	9,241,507
Term deposits	414,784	405,140
	<u>72,733,310</u>	<u>35,456,145</u>
b) Foreign currencies		
Cash on hand	2,645,697	180,130
Current accounts	7,944,814	16,722,000
	<u>10,590,511</u>	<u>16,902,130</u>
	<u>83,323,821</u>	<u>52,358,275</u>

Cash balances are represented in the following currencies:

	<i>30 September 2024</i> <i>EGP</i>	<i>31 December 2023</i> <i>EGP</i>
Egyptian pound (EGP)	72,733,310	35,456,145
US dollar (USD)	7,291,914	15,306,487
Euro (EUR)	3,298,597	1,595,643
	<u>83,323,821</u>	<u>52,358,275</u>

For the purpose of cash flow statements cash and cash equivalents consist of following:

	<i>30 September 2024</i> <i>EGP</i>	<i>30 September 2023</i> <i>EGP</i>
Cash in hand	2,646,748	3,833,784
Checks under collection	3,962,686	9,670,041
Current accounts	76,299,603	46,638,021
	<u>82,909,037</u>	<u>60,141,846</u>

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

12- Other Assets

	<i>30 September 2024</i>	<i>31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>
Real estate Units	<u>93,839,078</u>	-
	<u>93,839,078</u>	-

The other assets consist of the purchase value of real estate units (residential units) that were transferred to Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) "Parent Company" under a preliminary sale contract dated August 28, 2024, from one of the company's clients in exchange for settling a debt owed by him. The company determined the purchase price based on the purchase price of similar real estate units in the Egyptian real estate market.

13- PROVISIONS

	<i>Balance as at 1 January 2024</i>	<i>Charged during the period</i>	<i>Used during the period</i>	<i>Balance as at 30 September 2024</i>
	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>
Provision for expected claims	5,808,097	500,000	-	6,308,097
Provision for sales returns*	9,226,371	1,686,376	-	10,912,747
	<u>15,034,468</u>	<u>2,186,376</u>	-	<u>17,220,844</u>

	<i>Balance as at 1 January 2023</i>	<i>Charged during the year</i>	<i>Used during the year</i>	<i>Balance as at 31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>
Provision for expected claims	5,550,001	673,282	(415,186)	5,808,097
Provision for sales returns*	8,608,104	618,267	-	9,226,371
	<u>14,158,105</u>	<u>1,291,549</u>	<u>(415,186)</u>	<u>15,034,468</u>

*Provision for sales returns is deduced from sales disclosed (note 20).

14- TRADE, NOTES PAYABLES AND OTHER PAYABLES

	<i>30 September 2024</i>	<i>31 December 2023</i>
	<i>EGP</i>	<i>EGP</i>
Trade payables	195,916,747	102,405,625
Notes payables	20,022,624	37,700,531
Accrued expenses	71,554,628	58,644,065
Tax authority (other than income tax)	13,809,005	17,800,462
Advances from customer	31,852,169	10,431,219
Other payables	76,548,430	5,202,790
	<u>409,703,603</u>	<u>232,184,692</u>

Trade, notes payables accrued expenses and other payables are non-interest bearing.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

15- CAPITAL

The Company's authorized capital amounted to EGP 1 billion, whereas the issued and paid up capital amounted to EGP 378,233,733 divided over 1,512,934,932 shares of par value EGP 0.25 each.

Based on the decision of the Extraordinary General Assembly on October 14, 2020, the meeting of the Board of Directors held on January 4, 2023 decided to increase the company's issued and paid-up capital from 250,000,000 Egyptian pounds to 252,112,680 Egyptian pounds, an increase of 2,112,680 Egyptian pounds distributed over 8,450,720 shares, funded by the payments of the beneficiaries of the system provided that the increase is allocated entirely for the benefit of the system of rewarding and motivating the company's employees, so that the company's issued capital after the increase will be 252,112,680 Egyptian pounds paid in full distributed over 1,008,450,720 shares with a nominal value of 0.25 Egyptian pounds. The amount paid under capital increase reached EGP 2,112,680 as of 31 December 2023.

According to the bank certificate issued by Arab Bank on January 9, 2023, the company's issued and paid-up capital was increased from 250,000,000 EGP to 252,112,680 EGP, an increase of 2,112,680 EGP distributed over 8,450,720 shares (Note 17).

The extraordinary General Assembly meeting held on August 16, 2023 decided to increase the paid-in capital by 127,887,320 Egyptian pounds by distributing bonus shares of 0.52253 free shares for each original share of the company's shares before the increase of 978,980,720 shares after excluding treasury shares with reparations in favor of small shareholders from the smallest to The largest has to finance the increase in shares from the company's distributable net profits (profits for the year + retained earnings) for the fiscal year ending on December 31, 2022, so the company's issued capital after the increase becomes 380,000,000 Egyptian pounds distributed over 1,520,000,000 shares with a nominal value of EGP 0.25 per share and was registered in commercial register dated September 20, 2023.

The extraordinary General Assembly meeting held on August 16, 2023 decided to Reduce the issued and paid-up capital from 380,000,000 Egyptian pounds to 375,000,000 Egyptian pounds, a reduction of 5,000,000 Egyptian pounds, by retiring treasury shares listed under shares (shareholders through public and private offering) by 20,000,000 shares with a nominal value of 0.25 per share.

Based on the decision of the Extraordinary General Assembly on October 14, 2020, the meeting of the Board of Directors held on May 27, 2024 decided to increase the company's issued and paid-up capital from 375,000,000 Egyptian pounds to 378,233,733 Egyptian pounds, an increase of 3,233,733 Egyptian pounds distributed over 12,934,932 shares, funded by the payments of the beneficiaries of the system provided that the increase is allocated entirely for the benefit of the system of rewarding and motivating the company's employees, so that the company's issued capital after the increase will be 378,233,733 Egyptian pounds paid in full distributed over 1,512,934,932 shares with a nominal value of 0.25 Egyptian pounds.

According to the bank certificate issued by Arab Bank on June 2, 2024, the company's issued and paid-up capital was increased from 375,000,000 EGP to 378,233,733 EGP, an increase of 3,233,733 EGP distributed over 12,934,934 shares.

The structure for shareholders as at 30 September 2024:

	%	<i>No. of shares</i>	<i>Amount EGP</i>
Main Shareholder's Shares	45.98%	682,612,959	173,894,617
Treasury Shares	0.63%	9,470,000	2,367,500
Other listed Free Shares in Stock Exchange Market	53.40%	820,851,973	201,971,616
	<u>100%</u>	<u>1,512,934,932</u>	<u>378,233,733</u>

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

15- CAPITAL - CONTINUED

The structure for shareholders as at 31 December 2023:

	%	<i>No. of shares</i>	<i>Amount EGP</i>
Main Shareholder's Shares	45.71%	685,593,073	171,398,268
Treasury Shares	0.63%	9,470,000	2,367,500
Other listed Free Shares in Stock Exchange Market	53.66%	804,936,927	201,234,232
	<u>100%</u>	<u>1,500,000,000</u>	<u>375,000,000</u>

16- GENERAL RESERVE

The balance of general reserve - issuance premium is representing the net book value of issuing capital increase shares during 2019 amounted EGP 486,965,000 for issuing 125,000,000 Shares after deducting issuing cost of EGP 64,285,000.

Pursuant to Article (94) of the executive regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of 89,443,610 Egyptian pounds has been transferred to the legal reserve, amounting to 50% of the value of the issued and paid-up capital.

The capital was reduced by retiring 20,000,000 shares amounted 5,000,000 Egyptian pounds, with a nominal value of 0.25 per share, and an amount of 34,694,932 Egyptian pounds from the general reserve balance, which represents the difference between the market value of the purchased shares and the nominal value.

17- TREASURY SHARES

The board members meeting held on February 23, 2022, May 31, 2022, and 4 September 2022 decided to re-purchase treasury shares up to 10% of the total shares of the company's issued capital available in the market.

According to board of director resolutions on 23 February 2022, May 31, 2022, and 4 September 2022, the company purchased 29,470,000 shares from the stock market and held in treasury for a total consideration of EGP 65,926,198. The consideration paid has been accounted for as a reserve in the statement of shareholder's' equity.

During March 2022, the company purchased 20 million shares as treasury shares amounted to 39,694,932 EGP, and according to Article 48 of Law 159 of 1981, the company must dispose its treasury shares to others within a period of not more than one year from obtaining them otherwise it shall reduce its capital by the equivalent of the nominal value of these stocks.

Currently, the company is taking the necessary actions to reduce its capital by the nominal value of the treasury stocks with a total value of 5,000,000 EGP.

The Board of Directors meeting held on May 13, 2024 decided to approve the procedures for reducing capital by disposing of the company's treasury shares, which number 9,470,000 shares, for an amount of EGP 2,365,500 and the procedures are still in effect.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

18- SHARE BASED PAYMENT RESERVE

The company has approved the reward and incentive program for employees, managers and executive board members under the program the company grant the beneficiaries Ordinary share options at the nominal value in accordance with the approval of the Extraordinary General Assembly on October 14, 2020, and this program allows employees, managers and executive board members who benefit from the incentive and reward system to own part of the company's shares in accordance to listing and Trading Rules of Egyptian Stock Exchange under the provisions of Law 159 for year 1981 and its executive regulations and under the provision of law 95 for year 1992 and its executive regulations .

On 12 May 2024 the company activated the reward and incentive program. Giving number of employees, managers and executive board members share options for total of 9,681,733 shares at the nominal value (0.25 EGP per share) on condition of staying in service for the required period till the exercise date on 1 November 2023 an archiving the required performance appraisal. Each employee was granted maximum number of shares according to contracts giving one month period from the exercise date to exercise the purchasing right.

The fair value of the granted shares for numbers of employees were 9,584,917 Egyptian Pound using the price of the share announced in the Egyptian Stock Exchange on the grant date (1.98 EGP for share) before the deduction of the nominal value of shares that would be paid by the beneficiaries in cash.

Movement of Equity instruments in the period / year as follow:

	30 September 2024		31 December 2023	
	Amount EGP	Shares No.	Amount EGP	Shares No.
Beginning of the period / year	13,927,085	13,138,759	14,873,267	8,450,720
Granted during the period / year	8,374,699	9,681,733	13,927,085	13,138,759
Exercised during the period / year	(13,927,085)	(13,138,759)	(14,873,267)	(8,450,720)
End of the period / year	<u>8,374,699</u>	<u>9,681,733</u>	<u>13,927,085</u>	<u>13,138,759</u>

19- CREDIT FACILITIES

The movement of the credit facilities during the period is as follows:

	30 September 2024 EGP	31 December 2023 EGP
Opening balance	1,057,762,833	893,644,592
Used during the period / year	1,490,560,423	1,429,210,500
Payment during the period / year	(1,432,448,439)	(1,265,092,259)
Ending balance	<u>1,115,874,817</u>	<u>1,057,762,833</u>

	30 September 2024 EGP	31 December 2023 EGP
Credit facilities maturing within 12 months	1,115,874,817	1,057,762,833
Bank credit	154,309	2,458,485
	<u>1,116,029,126</u>	<u>1,060,221,318</u>

- The interest rate on the Credit facilities ranges from 11% to 27.44% as of 30 September 2024 (31 December 2023: Range from 8% to 20.75%).

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

19- CREDIT FACILITIES - CONTINUED

Credit Facilities	Facility amount EGP	<i>30 September 2024</i>	<i>31 December 2023</i>
		<i>EGP</i>	<i>EGP</i>
CIB	600,000,000	280,839,781	326,662,581
FAB Bank	125,000,000	115,859,144	118,301,989
Arab Bank	118,000,000	81,486,060	100,823,368
ABK Bank	120,000,000	12,511,547	89,908,853
ADIB	209,000,000	122,647,340	132,496,882
Alex Bank	170,000,000	-	42,789,875
AUB	130,000,000	129,706,834	79,808,945
ENBD	100,000,000	93,862,284	80,119,201
AWB	100,000,000	93,358,005	86,851,139
NBK	300,000,000	185,603,822	-
Total Credit Facilities		1,115,874,817	1,057,762,833

Some of the above facilities are guaranteed by notes receivable (note 9).

20- REVENUES

	Nine Months ended		Three months ended	
	<i>30 September 2024</i>	<i>30 September 2023</i>	<i>30 September 2024</i>	<i>30 September 2023</i>
	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>
Sale of goods (net)	1,667,178,727	1,282,853,178	719,880,705	510,919,076
Toll manufacturing services revenue	117,189,845	105,305,365	43,348,367	34,805,644
	1,784,368,572	1,388,158,543	763,229,072	545,724,720

21- COST OF REVENUES

	Nine Months ended		Three months ended	
	<i>30 September 2024</i>	<i>30 September 2023</i>	<i>30 September 2024</i>	<i>30 September 2023</i>
	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>	<i>EGP</i>
Salaries and incentives	112,689,882	92,094,015	36,911,489	29,647,327
Social insurance and other benefit	33,948,866	26,992,969	11,526,450	9,309,218
Raw materials	599,218,537	420,818,775	276,995,868	171,043,883
Spare parts and materials	36,972,258	23,734,247	14,446,436	8,454,123
Government fees and medical stamps	15,214,506	12,054,477	7,728,510	4,017,475
Other operating expenses	36,037,977	50,584,170	18,488,133	18,285,474
Energy expenses	42,231,266	33,787,280	19,046,164	11,645,423
Depreciation and amortization (Note 5.6 &7)	54,928,131	47,635,876	18,638,357	17,529,189
Rent	4,475,882	3,482,829	1,578,465	205,340
Maintenance	33,134,667	25,157,874	10,781,045	10,496,088
	968,851,972	736,342,512	416,140,917	280,633,540

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

22- SELLING & MARKETING EXPENSES

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Salaries and incentives	121,011,620	97,718,498	41,110,216	34,696,347
Social insurance and other benefit	14,004,673	10,609,927	4,760,010	3,622,466
Depreciation (Note 5,6)	3,983,864	3,794,307	1,328,914	1,291,126
Rent	65,900	38,400	37,500	-
Advertising and marketing	161,093,006	136,252,482	50,230,670	54,001,537
	300,159,063	248,413,614	97,467,310	93,611,476

23- GENERAL & ADMINISTRATIVE EXPENSES

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Salaries and incentives	57,791,987	44,779,627	19,124,845	15,560,932
Social insurance and other benefit	3,809,069	2,848,612	1,294,877	976,988
Professional fees	6,128,020	3,944,963	1,448,646	928,228
Maintenance	1,728,524	1,333,948	582,077	500,338
Depreciation (Note 5)	1,579,125	1,498,727	505,470	506,159
Others	7,912,616	9,732,599	2,614,003	3,878,830
	78,949,341	64,138,476	25,569,918	22,351,475

24- FINANCE INCOME

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Interest from treasury bills	50,439,243	46,940,704	16,201,993	16,500,623
Interest from time deposits	701,917	668,935	346,915	337,834
	51,141,160	47,609,639	16,548,908	16,838,457

25- FINANCE EXPENSES

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Debit interests	201,643,184	131,032,234	65,672,090	57,151,112
Unwinding interests of lease liabilities (Note 6)	1,179,819	1,562,739	355,151	495,519
Bank Charges	2,520,828	2,089,448	819,624	903,687
	205,343,831	134,684,421	66,846,865	58,550,318

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

26- INCOME TAXES

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Current income tax	(51,379,475)	(54,463,439)	(39,467,414)	(23,312,020)
Deferred income tax	(21,857,335)	(2,873,884)	2,836,846	1,178,741
Income tax expense	<u>(73,236,810)</u>	<u>(57,337,323)</u>	<u>(36,630,568)</u>	<u>(22,133,279)</u>

DEFERED INCOME TAXES

	Statement of financial position		Statement of profit or loss	
	30 September 2024 EGP	31 December 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Fixed assets and intangible assets	(81,591,281)	(70,926,537)	(10,664,744)	(7,000,922)
Provisions	2,442,903	2,075,933	366,970	-
Impairment of trade and notes receivables	4,580,256	3,309,050	1,271,206	604,892
Write down in value of inventory	4,084,076	5,588,023	(1,503,947)	3,279,448
Share based payment	5,017,901	3,133,594	1,884,307	(1,742,076)
Unrealized foreign exchange differences	(14,564,197)	(148,972)	(14,476,616)	3,250,263
Others	-	(1,265,489)	1,265,489	(1,265,489)
Net deferred income taxes	<u>(80,030,342)</u>	<u>(58,234,398)</u>	<u>(21,857,335)</u>	<u>(2,873,884)</u>

RECONCILIATION OF THE EFFECTIVE INCOME TAX RATE

	Tax Rate	30 September 2024 EGP	Tax Rate	30 September 2023 EGP
Profits before income taxes		317,272,440		254,316,298
Income tax based on tax rate	22.50%	71,386,299	22.50%	57,221,167
Non-deductible expenses		1,850,511		116,156
Effective Tax Rate	23.08%	<u>73,236,810</u>	22.55%	<u>57,337,323</u>

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

27- EARNINGS PER SHARE

Basic and diluted earnings per share were calculated by dividing the profits for the period available for distribution to the Parent Company by the weighted average number of shares outstanding during the period as follows:

	Nine Months ended		Three months ended	
	30 September 2024 EGP	30 September 2023 EGP	30 September 2024 EGP	30 September 2023 EGP
Net profit for the period attributable to ordinary shares	234,523,174	191,963,850	115,678,403	76,288,972
Weighted average number of shares outstanding after purchase of treasury shares during the period	1,494,015,246	1,490,530,000	1,494,015,246	1,490,530,000
Effect of diluted shares:				
Share Options for employees and executive managers	5,229,488	6,445,203	5,229,488	6,445,203
Weighted average number of ordinary shares adjusted for the effect of dilution during the period	1,499,244,734	1,496,975,203	1,499,244,734	1,496,975,203
Earnings per share – Basic	0.1570	0.1288	0.0774	0.0512
Earnings per share - Diluted	0.1564	0.1282	0.0772	0.0510

28- TAX POSITION

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

a) Corporate Tax

- The Company's records were inspected till the year 2013 and the due tax has been paid.
- The years from 2014 to 2017 were inspected as an estimate and were challenged and a decision was issued to re-examine the actual inspection has been done and the dispute is under settlement.
- The years 2018 and 2019 have been inspected and the forms were issued and the dispute are under settlement.

b) Salary Tax

- The Company's records were inspected till the period 2015 and the taxes differences were paid and settled.
- Periods from 2016 to 2019 the documents related to the inspection were submitted and the tax due in the settlements was paid.
- The Company's records were inspected for year 2020 and the and the due tax has been paid.

c) Stamp Tax

- The Company's records were inspected till 2013 and the taxes due were paid.
- The years from 2014 to 2020 were inspected and the dispute are under settlement.

d) Sales Tax

- The Company's records were inspected till the period 2015 and the due tax has been paid.

e) VAT Tax

- The Company's books were examined from 2016 to 2019 and the due tax has been paid.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

28- TAX POSITION – COUNTUNED

RAMEDA FOR PHARMACEUTICAL TRADING (S.A.E)

a) Corporate Tax

- The company provides legal procedures within the legal dates according to law 91 of year 2005.
- The company has been inspected and paid for years 2012 to 2021

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The company has not been notified of the examination to now.

d) VAT

- The company was examined from the beginning of registration 8/2018 until 8/2019, and the appeal was made and the file was referred to the appeal committee.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

RAMECARE COMPANY (L.L.C.)

a) Corporate Tax

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The company was notified of a tax form (19) for the years 2015/2016, and it was appealed on the legal date, and the necessary documents are being prepared for re-examination.
- The company was notified of Form (19) tax for the years 2017, and it was appealed on the legal dates.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The years from the beginning of the activity until the year 2020.

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the three-month and nine-month periods ended 30 September 2024

28- TAX POSITION - CONTINUED**RAMEPHARMA COMPANY (L.L.C.)****a) Corporate Tax**

- The company submits tax returns on legal dates in accordance with Law No. 91 of 2005.
- The company was notified of the form (19) tax for year 2017, and it was appealed within the legal deadline.

b) Salary Tax

- The company has not been notified of the examination to now.

c) Stamp Tax

- The company has not been notified of the examination to now.

d) VAT

- The company has not been notified of the examination to now.

e) Social Insurance

- No insurance file has been opened for the company to date.

f) Withholding Tax

- The company has not been notified of the examination to now.

29- MAJOR EVENTS

Fitch Ratings Agency has forecasted an increase in Egypt's economic growth rate to 5.3% in the next fiscal year 2025-2026, compared to 4% in the current fiscal year 2024-2025, and 2.4% in the previous fiscal year. Fitch has also upgraded Egypt's long-term foreign currency credit rating from B- to B with a stable outlook.

30- NEW VERSIONS AND AMENDMENTS TO THE EGYPTAIN ACCOUNTING STANDARDS

On 3 March 2024, the Prime Minister's Resolution No. (636) of 2024 was issued amending certain provisions of accounting standards, where he agreed to replace the following standards: EAS (13) "Effects of Changes in Foreign Exchange Rates" with the revised EAS (13) "Effects of Changes in Foreign Exchange Rates", EAS (17) "Separate Financial Statements" with the revised EAS (17) "Separate Financial Statements," and EAS (34) "Real Estate Investment" with the revised EAS (34) "Real Estate Investment", of the aforementioned Egyptian accounting standards, enclosed with such Resolution. Further, the Egyptian Accounting Interpretation (2) "Carbon Emission Reduction Certificates" enclosed with such Resolution has been added.

On 23 October 2024, the Prime Minister's Resolution No. (3527) of 2024 was issued amending certain provisions of accounting standards by adding new EAS (51) "Financial Reporting in Hyperinflationary Economies".